| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | 4 | — | — | — | — |
| Sell | — | — | — | — | 1 | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 109.93 | 65.51 | 54.74 | 92.85 |
| Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 114.79 | 67.84 | 61.25 | 97.25 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 0.98 | 0.28 | 0.13 | 0.83 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 9.26 | 6.24 | 4.22 | 3.57 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.21 | — | — | — |
—
|
| ’25 | 0.21 | 0.21 | 0.21 | 0.22 |
0.86
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (7.98) | 45.92 | — | — |
—
|
| ’25 | (10.20) | (8.38) | (6.55) | (4.68) |
(29.81)
|
| ’24 | (15.46) | (10.42) | (13.54) | (9.86) |
(49.28)
|
| ’23 | (18.76) | (13.38) | (16.47) | (11.64) |
(60.26)
|
| ’22 | (13.73) | (13.55) | (14.73) | (15.26) |
(57.28)
|
| ’21 | (11.93) | (12.85) | (10.87) | (9.89) |
(45.53)
|
| ’20 | — | (9.15) | (5.62) | (7.26) |
(22.04)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (7.98) | 45.92 | — | — |
—
|
| ’25 | (10.20) | (8.38) | (6.55) | (4.68) |
(29.81)
|
| ’24 | (15.46) | (10.42) | (13.54) | (9.86) |
(49.28)
|
| ’23 | (18.76) | (13.38) | (16.47) | (11.66) |
(60.28)
|
| ’22 | (13.77) | (13.57) | (14.74) | (15.26) |
(57.34)
|
| ’21 | (11.99) | (12.85) | (11.00) | (10.02) |
(45.87)
|
| ’20 | — | (9.16) | (5.65) | (7.37) |
(22.18)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.46) | 7.53 | — | — |
—
|
| ’25 | (1.68) | (1.76) | 2.88 | — |
(1.59)
|
| ’24 | (3.76) | (2.96) | (2.08) | (2.00) |
(10.64)
|
| ’23 | (3.44) | (3.68) | (3.60) | (4.00) |
(14.72)
|
| ’22 | (3.84) | (4.56) | (4.80) | (3.68) |
(16.72)
|
| ’21 | (0.41) | (22.40) | (2.96) | (3.36) |
(14.72)
|
| ’20 | — | — | — | — |
(0.82)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | ‡‡‡‡‡ | 36.32 | 13.76 | 6.73 | 1.76 | — | — | — |
Low Price
|
| — | — | — | — | — | ‡‡‡‡‡ | 127.12 | 79.00 | 27.68 | 8.64 | — | — | — |
High Price
|
| — | — | — | — | ‡‡‡‡ | ‡‡‡‡ | 41 | 43 | 25 | 14 | — | — | — |
Employees
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.03 | 0.06 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | 0.64 | 0.86 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | — | 100.00% | 100.00% | — | — | — |
Gross Margin
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (65.58) | (72.52) | (55.54) | (8.10) | — | — | — |
EBT
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | (8,732.08%) | (944.52%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (66.65) | (74.56) | (57.77) | (8.98) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.27) | (2.94) | (1.48) | (0.48) | — | — | — |
Depreciation
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.12 | 0.15 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Revenue/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (16.72) | (14.72) | (10.64) | (1.59) | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.40) | (11.92) | (9.05) | (5.30) | — | — | — |
Cash Flow/Sh
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.01) | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.42) | (11.92) | (9.05) | (5.30) | — | — | — |
Free CF/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 42.57 | 21.00 | 11.33 | 10.29 | ‡‡‡‡ | — | — |
Book Value/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.98 | 5.06 | 5.44 | 5.63 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | — | 0.00 | 36.02 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | 0.68 | 0.53 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | 0.00 | (27.27) | ‡‡‡‡ | ‡‡‡‡ | — |
EV/Sales
|
| — | — | — | — | — | — | — | — | 0.47 | 0.78 | — | — | — |
EV/FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (57.28) | (60.26) | (49.28) | (29.81) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.05) | (0.01) | — | — | — | — | — |
Capex
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (57.34) | (60.28) | (49.28) | (29.81) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 168.75 | 105.53 | 61.60 | 57.03 | — | — | — |
Working Cap'
|
| — | — | — | — | — | — | 0.56 | — | — | — | — | — | — |
Total Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (168.44) | (109.93) | (65.51) | (54.74) | — | — | — |
Net Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 169.32 | 106.18 | 61.65 | 57.96 | — | — | — |
Sh' Equity
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (36.76%) | (50.37%) | (62.89%) | (13.77%) | — | — | — |
ROA
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (4,832.29%) | 0.00% | 0.00% | (641.77%) | — | — | — |
ROIC
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (38.65%) | (54.13%) | (68.85%) | (15.01%) | — | — | — |
ROE
|
Rallybio Corporation (RLYB), a clinical-stage biotech targeting rare diseases, embodies the sector’s high-risk volatility amid post-2021 derating driven by Fed rate hikes and capital scarcity. Since its SPAC debut, shares soared on pipeline hype around assets like RLYB2128 before plunging over 90% from peaks, tracking clinical delays, mounting losses, and biotech funding winters. Now trading at levels implying deep undervaluation versus analyst consensus— with a uniform 66% upside target—RLYB shows stabilization signals: 2024 revenue debut at $636K, 42% headcount cut, and net cash of $65M funding 3-4 years of $50M+ annual burns, though EPS and FCF remain deeply negative.
Financials reveal classic pre-revenue pressures—losses peaking at -$74M in 2023 before easing, with projections for renewed widening to -$28M by 2027—but per-share metrics brighten via 88% share count contraction, hinting at efficiency or restructuring. Stock resilience flickers in bounces tied to cost controls, contrasting zero insider activity amid stagnant prices. Pipeline catalysts, like RLYB2128 Phase 2 resumption, could unlock non-dilutive funding or M&A in a sector eyeing 20-30% rebounds from anticipated 2025-2027 Fed cuts to 3-4%, easing discount rates on distant cash flows.
In a macro thaw—bolstered by inflation moderation and despite IRA price risks—RLYB positions as a speculative recovery bet, where trial wins could outweigh persistent bleeds and ignite returns in thawing biotech liquidity.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.